Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (21881)	6/5/1998 8:14:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

The leptin delay was due to problems in the negotiations. The Science article is essentially "in press". The two events are really not comparable. (Actually, I would put the current rumor source in a category that is MORE reliable than IR). I would be VERY surprised if the article was not published this month. Actually, there should be several news items this month, based in part by the recent BARS report on ONTAK.

To: Skeeter Bug who wrote (21881)	6/5/1998 8:24:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

I wonder if this 'major news' will be in the "print version" or only in the "on-line" version :-) (Does anyone remember the 'major' Ligand Interview (the one that made Ligand a 'household name') that was in Business Week (the on-line version only))?

To: Skeeter Bug who wrote (21881)	6/5/1998 8:34:00 AM
From: Henry Niman	Respond to of 32384

Actually, the Science article will be on-line and in the printed version. Although most scientists get Science's printed version, more and more rely upon the on-line version because of hot links, etc. I expect the Science article to generate a fair amount of news in the printed version of the popular press also. How long it takes for the public and street to grasp the significance of the publication is of course a major wild card. As you know, the three diabetes articles that were predicted (Business Week, Financial Times, and NY Times) were all published, although the publications were a bit later than expected (due in part by the liver enzyme elevations linked to Rezulin). The Business Week and NY Times articles are linked to home.att.net under Background Info.